Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for RO.SW and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for RO.SW and 80,000+ other tickers.
See exactly how RO.SW's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RO.SW and 80,000+ other tickers.
Roche Holding AG is a global healthcare enterprise with dual focuses: pharmaceuticals and diagnostics. The company maintains a significant presence in numerous countries, including its home base in Switzerland, alongside Germany, the United States, Austria, the Netherlands, the United Kingdom, France, Belgium, and various other international markets. Its pharmaceutical segment develops and supplies treatments for a wide spectrum of medical conditions, encompassing oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory…
Konzernverkäufe stiegen in den ersten sechs Monaten um6% zu konstanten Wechselkursen (CER1; in CHF ausgewiesen -2% und auf USD-Basis28%) aufgrund hoher Nachfrage nach innovativen Medikamenten und Diagnostika. Verkäufe der Division Pharma erhöhten sich um6% (CER; in CHF ausgewiesen -1% und auf USD-Basis8%) aufgrund des kontinuierlich hohen Umsatzwachstums unserer Medikamente in allen Therapiebereichen; die wichtigsten Wachstumstreiber waren Xolair (allergisches Asthma, chronische Nesselsucht, Nahrungsmittelallergien), Hemlibra (Hämophilie A), Ocrevus (Multiple Sklerose), Phesgo (Brustkrebs) und Vabysmo (schwere Augenerkrankungen).
AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise their workflows and explore a wider array of applications. Powered by innovative SBX technology, the platform is capable of end-to-end, same-day whole-genome sequencing in research workflows, with accurate results within hours.
The new VENTANA PTEN (SP218) RxDx Assay fulfils an unmet medical need by helping clinicians identify patients with PTEN protein loss who may benefit from combination treatment with TRUQAP In prostate cancer, PTEN protein loss is associated with faster disease progression and reduced benefit from current standard-of-care treatments1 The FDA approval reinforces Roche's leadership in companion diagnostics and its ongoing commitment to expanding personalised healthcare to improve patient outcomes Basel, 12 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the VENTANAⓇ PTEN (SP218) RxDx Assay is the first immunohistochemistry (IHC) companion diagnostic test to receive U.
Filing acceptance, under priority review, based on phase III data showing giredestrant reduced the risk of invasive disease recurrence or death by 30% compared with standard-of-care endocrine therapy1Giredestrant represents the first significant advance in adjuvant endocrine therapy in over 20 years1-3Giredestrant has the potential to become a new standard-of-care in the adjuvant setting; more than 90% of ER-positive breast cancer cases are diagnosed at an early-stage (I-III)4-7The FDA has set a Prescription Drug User Fee Act date of 30 November 2026 Basel, 02 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States (US) Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) under Priority Review for giredestrant, an investigational oral selective oestrogen receptor degrader (SERD), as an adjuvant treatment for adults with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, stage I, II, and III breast cancer.
Late-breaking Phase II data highlight enicepatide's (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesityLate-breaking data from the Phase II ZUPREME-1 trial showcase petrelintide's efficacy, safety, and compelling tolerability profile, which has the potential to redefine the weight management experience for people living with overweight or obesityA Phase II multi-arm trial evaluating enicepatide and petrelintide fixed-dose combinations will be initiated towards mid-2026 to develop a differentiated treatment option Basel, 1 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that new data from its obesity portfolio will be presented at the 2026 Scientific Sessions of the American Diabetes Association (ADA).